David J. Einstein

1.3k total citations
71 papers, 544 citations indexed

About

David J. Einstein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, David J. Einstein has authored 71 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 16 papers in Cancer Research. Recurrent topics in David J. Einstein's work include Prostate Cancer Treatment and Research (40 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). David J. Einstein is often cited by papers focused on Prostate Cancer Treatment and Research (40 papers), Radiopharmaceutical Chemistry and Applications (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). David J. Einstein collaborates with scholars based in United States, Germany and Canada. David J. Einstein's co-authors include Guru Sonpavde, Steven P. Balk, David F. McDermott, Paul Mathew, Brian Halbert, Seiji Arai, Katherine Levine Einstein, Mark A. Preston, Mary K. Buss and Bradley A. McGregor and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

David J. Einstein

64 papers receiving 536 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David J. Einstein United States	13	258	226	150	133	125	71	544
Kyle A. Blum United States	13	421 1.6×	146 0.6×	169 1.1×	234 1.8×	114 0.9×	47	604
Samuel Haywood United States	12	296 1.1×	170 0.8×	94 0.6×	111 0.8×	92 0.7×	49	545
Ruey-Kuen Hsieh Taiwan	14	266 1.0×	295 1.3×	104 0.7×	145 1.1×	60 0.5×	44	664
Raj P. Pal United Kingdom	10	177 0.7×	129 0.6×	79 0.5×	147 1.1×	69 0.6×	21	420
Ram Eitan Israel	16	59 0.2×	133 0.6×	236 1.6×	150 1.1×	158 1.3×	73	805
Vincent Dochez France	10	70 0.3×	116 0.5×	165 1.1×	154 1.2×	108 0.9×	47	692
Shannon Salvador Canada	18	69 0.3×	143 0.6×	207 1.4×	95 0.7×	70 0.6×	74	959
Sudhir Isharwal United States	15	413 1.6×	103 0.5×	123 0.8×	214 1.6×	50 0.4×	37	567
Bartosz Małkiewicz Poland	12	162 0.6×	109 0.5×	221 1.5×	69 0.5×	35 0.3×	89	491
Amir H. Lebastchi United States	14	143 0.6×	77 0.3×	214 1.4×	93 0.7×	48 0.4×	27	494

Countries citing papers authored by David J. Einstein

Since Specialization

Citations

This map shows the geographic impact of David J. Einstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Einstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Einstein more than expected).

Fields of papers citing papers by David J. Einstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Einstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Einstein. The network helps show where David J. Einstein may publish in the future.

Co-authorship network of co-authors of David J. Einstein

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Einstein. A scholar is included among the top collaborators of David J. Einstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Einstein. David J. Einstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravi, Praful, Lucia Kwak, Andrés Acosta, et al.. (2025). Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer. European Urology. 87(6). 643–650. 1 indexed citations

Wilson, Rebekah L., Alicia K. Morgans, Mary K. Norris, et al.. (2025). Design of debunking the frailty–sarcopenia–ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol. Frontiers in Sports and Active Living. 7. 1602123–1602123.

Smith, Matthew R., Howard I. Scher, David J. Einstein, et al.. (2025). Darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead-in phase results.. Journal of Clinical Oncology. 43(5_suppl). 150–150.

Ku, Sheng‐Yu, et al.. (2025). Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer. Molecular Cancer Therapeutics. 25(2). 346–354.

Nouri, Mannan, Andreas Varkaris, Maya Ridinger, et al.. (2024). AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. Molecular Cancer Therapeutics. 23(10). 1404–1417. 3 indexed citations

Einstein, David J., Brian Halbert, Thomas Denize, et al.. (2024). Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy. Journal of Immunotherapy. 47(9). 361–368. 3 indexed citations

Hoffman, Richard M., Paul L. Nguyen, Dana E. Rathkopf, et al.. (2024). Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy. International Journal of Radiation Oncology*Biology*Physics. 120(2). S54–S54.

Hoffman, Karen E., Paul L. Nguyen, Dana E. Rathkopf, et al.. (2024). Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).. Journal of Clinical Oncology. 42(4_suppl). 260–260.

Sadagopan, Ananthan, Chunyang Bao, Jiao Li, et al.. (2024). A genetic basis for sex differences in Xp11 translocation renal cell carcinoma. Cell. 187(20). 5735–5752.e25. 9 indexed citations

10.

Dodge, Laura E., et al.. (2023). Prevalence and Morbidity of Local Treatment-Related Side Effects in Metastatic Prostate Cancer Patients. Urologic Oncology Seminars and Original Investigations. 41(4). 204.e1–204.e6. 3 indexed citations

11.

Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 11(3). e004780–e004780. 19 indexed citations

12.

Nguyen, Paul L., Marisa Kollmeier, Dana E. Rathkopf, et al.. (2023). FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP). International Journal of Radiation Oncology*Biology*Physics. 117(2). S81–S82. 1 indexed citations

13.

Ramalingam, Vijay, et al.. (2023). Percutaneous CT-Guided Cryoablation for Locally Recurrent Prostate Cancer: Technical Feasibility, Safety, and Effectiveness. Journal of Vascular and Interventional Radiology. 35(1). 36–44. 2 indexed citations

14.

Patterson, Jesse C., Andreas Varkaris, Peter J.P. Croucher, et al.. (2022). Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Research. 83(2). 219–238. 12 indexed citations

15.

Quinn, Zachary L., Benjamin E. Leiby, Guru Sonpavde, et al.. (2022). Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clinical Cancer Research. 29(1). 50–59. 18 indexed citations

16.

Einstein, David J., Seiji Arai, Carla Calagua, et al.. (2021). Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. JCO Precision Oncology. 1514–1522. 8 indexed citations

17.

Halbert, Brian & David J. Einstein. (2020). Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. Urology. 147. 119–126. 24 indexed citations

18.

Bilušić, Marijo, David J. Einstein, Fatima Karzai, et al.. (2020). The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. Urologic Clinics of North America. 47(4). 457–467. 8 indexed citations

19.

Trostel, Shana Y., Olga Voznesensky, Rachel Schaefer, et al.. (2019). Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precision Oncology. 3(3). 1–13. 49 indexed citations

20.

Einstein, David J., Seiji Arai, & Steven P. Balk. (2019). Targeting the androgen receptor and overcoming resistance in prostate cancer. Current Opinion in Oncology. 31(3). 175–182. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact